Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Brinzolamid + Brimonidin, ATC S01EC24 für die Zeit 01.09.2026 - 31.08.2028 (zzgl. V.-Option 1x12 Monate)

Section 130a, paragraph 8, of the German Social Code Book V (SGB V) enables health insurance companies and pharmaceutical companies to conclude framework rebate contracts for medicines to be dispensed at the expense of the statutory health insurance. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly conducts substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the German Competition Act (GWB). For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned active substance Brinzolamide + Brimonidine, ATC S01EC24, the DAK-Gesundheit intends to conclude medicine rebate contracts with as many interested pharmaceutical companies as possible until new medicine rebate contracts come into force. A rebate contract under the approval model for the aforementioned active substance comes into force for the first time on 01.09.2026 and ends on 31.08.2028 (plus extension option 1x12 months). It ends automatically with the entry into force of the exclusive contract, regardless.